Zhitong Finance App News, Recco Bio-B (02179.HK) announced that the phase III clinical trial of the new adjuvant recombinant herpes zoster vaccine REC610 independently developed by the group has been completed. Registration number: CTR20243742. The company has recently obtained the clinical trial summary report of this study.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Recco Bio-B (02179.HK) announced that the phase III clinical trial of the new adjuvant recombinant herpes zoster vaccine REC610 independently developed by the group has been completed. Registration number: CTR20243742. The company has recently obtained the clinical trial summary report of this study.